<p>HighVista Strategies LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Praxis Precision Medicines, Inc.（NASDAQ:PRAX - 免费报告）的股份增加了 71.3%。该基金在季度内购买了额外的 28,002 股后，持有该公司 67,288 股股票。Praxis Precision Medicines 占 HighVista Strategies LLC 持有资产的 1.0%，使其成为该基金第 22 大持股。截至最近向 SEC 提交的文件，HighVista Strategies LLC 持有的 Praxis Precision Medicines 约占 0.32%，价值 2,829,000 美元。</p>
<p>其他一些机构投资者最近也买卖了 PRAX 的股票。Adage Capital Partners GP L.L.C. 在第一季度将其在 Praxis Precision Medicines 的持仓增加了 188.1%。Adage Capital Partners GP L.L.C. 现在拥有 1,742,758 股该公司的股票，价值 65,998,000 美元，此前在上个季度又收购了 1,137,748 股。Driehaus Capital Management LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 192.0%。Driehaus Capital Management LLC 现在拥有 481,598 股该公司的股票，价值 18,238,000 美元，此前在上个季度又收购了 316,686 股。Vivo Capital LLC 在第二季度购买了价值约 7,048,000 美元的 Praxis Precision Medicines 新头寸。Woodline Partners LP 在第一季度将其在 Praxis Precision Medicines 的持股增加了 1,666.5%。Woodline Partners LP 现在拥有 175,727 股该公司的股票，价值 6,655,000 美元，此前在上个季度又购买了 165,779 股。最后，Aberdeen Group plc 在第二季度将其在 Praxis Precision Medicines 的持仓提高了 143.5%。Aberdeen Group plc 现在拥有 214,056 股该公司的股票，价值 9,001,000 美元，此前购买了 126,153 股。67.84% 的股票目前由机构投资者持有。</p>
<h2>内部人士买卖</h2>
<p>在其他消息中，内部人士 Lauren Mastrocola 于 11 月 20 日星期四出售了 13,600 股 Praxis Precision Medicines 的股票。该股票以平均价格 192.08 美元出售，总价值为 2,612,288.00 美元。交易完成后，内部人士直接持有该公司 10,442 股股票，价值约 2,005,699.36 美元。这笔交易代表其持仓减少了 56.57%。该出售在向 SEC 的法律文件中披露，可以通过此超链接访问。此外，法律顾问 Alex Nemiroff 于 11 月 20 日星期四出售了 25,130 股该公司的股票。该股票以平均价格 193.09 美元出售，总价值为 4,852,351.70 美元。交易完成后，法律顾问直接持有该公司 20,832 股股票，价值约 4,022,450.88 美元。这笔交易使其持有的股票减少了 54.68%。该出售的披露在 SEC 文件中可用。内部人士持有该公司 2.70% 的股票。</p>
<h2>Praxis Precision Medicines 价格表现</h2>
<p>Praxis Precision Medicines 的股票在星期四开盘价为 261.58 美元。该股票的市值为 65.4 亿美元，市盈率为 -20.28，贝塔值为 2.95。该公司的 50 日移动平均线为 163.26 美元，200 日移动平均线为 87.46 美元。Praxis Precision Medicines, Inc. 的 1 年最低价为 26.70 美元，1 年最高价为 278.44 美元。</p>
<p>Praxis Precision Medicines（NASDAQ:PRAX - 获取免费报告）最近于 11 月 5 日星期三公布了季度财报。该公司报告每股收益为 -3.36 美元，超出市场共识预期的 -3.45 美元，超出幅度为 0.09 美元。分析师平均预计，Praxis Precision Medicines, Inc. 今年的每股收益将为 -10.22 美元。</p>
<h2>分析师评级变动</h2>
<p>PRAX 一直是多份分析师报告的主题。Lifesci Capital 在 9 月 3 日星期三的研究报告中将 Praxis Precision Medicines 的评级上调至 “强烈买入”。德意志银行在 12 月 5 日星期五的报告中重申了 “买入” 评级，并设定了 303.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对 Praxis Precision Medicines 的 “卖出（e+）” 评级。TD Cowen 在周一的研究报告中将 Praxis Precision Medicines 的目标价从 251.00 美元上调至 353.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 12 月 5 日星期五的报告中重申了 “表现不佳” 评级，并将目标价设定为 83.00 美元（上调自 77.00 美元）。两位股票研究分析师对该股票给予了 “强烈买入” 评级，十三位给予了 “买入” 评级，两位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 333.00 美元。</p>
<p><strong>获取我们关于 Praxis Precision Medicines 的最新研究报告</strong></p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（免费报告）</p>
<p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗原发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Praxis Precision Medicines</li>
<li>除息日对投资者的重要性是什么？</li>
<li>GameStop 看起来崩溃了：以下是 GME 可能在 2026 年崩盘的原因</li>
<li>CD 计算器：定期存款计算器</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Casey’s General Stores 将继续上涨的 3 个原因</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Praxis Precision Medicines 吗？</h2>
<p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRAX

<p>HighVista Strategies LLC 在第二季度将其在 Praxis Precision Medicines 的持股增加了 71.3%。内部人士出售了股票，显著减少了他们的持股。该股票开盘价为 261.58 美元，市值为 65.4 亿美元。分析师的评级不一，有些将评级上调至 “强烈买入”，而其他则维持 “表现不佳”。该股票的 1 年最高价为 278.44 美元</p>

<p>HighVista Strategies LLC increased its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 71.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 67,288 shares of the company's stock after purchasing an additional 28,002 shares during the quarter. Praxis Precision Medicines accounts for 1.0% of HighVista Strategies LLC's holdings, making the stock its 22nd biggest holding. HighVista Strategies LLC owned approximately 0.32% of Praxis Precision Medicines worth $2,829,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>HighVista Strategies LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Praxis Precision Medicines, Inc.（NASDAQ:PRAX - 免费报告）的股份增加了 71.3%。该基金在季度内购买了额外的 28,002 股后，持有该公司 67,288 股股票。Praxis Precision Medicines 占 HighVista Strategies LLC 持有资产的 1.0%，使其成为该基金第 22 大持股。截至最近向 SEC 提交的文件，HighVista Strategies LLC 持有的 Praxis Precision Medicines 约占 0.32%，价值 2,829,000 美元。</p>
</div><p>A number of other institutional investors also recently bought and sold shares of PRAX. Adage Capital Partners GP L.L.C. increased its position in Praxis Precision Medicines by 188.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company's stock valued at $65,998,000 after acquiring an additional 1,137,748 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of Praxis Precision Medicines by 192.0% in the 1st quarter. Driehaus Capital Management LLC now owns 481,598 shares of the company's stock worth $18,238,000 after acquiring an additional 316,686 shares during the last quarter. Vivo Capital LLC purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth about $7,048,000. Woodline Partners LP grew its holdings in Praxis Precision Medicines by 1,666.5% during the 1st quarter. Woodline Partners LP now owns 175,727 shares of the company's stock valued at $6,655,000 after purchasing an additional 165,779 shares during the last quarter. Finally, Aberdeen Group plc raised its position in Praxis Precision Medicines by 143.5% in the 2nd quarter. Aberdeen Group plc now owns 214,056 shares of the company's stock worth $9,001,000 after purchasing an additional 126,153 shares during the period. 67.84% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了 PRAX 的股票。Adage Capital Partners GP L.L.C. 在第一季度将其在 Praxis Precision Medicines 的持仓增加了 188.1%。Adage Capital Partners GP L.L.C. 现在拥有 1,742,758 股该公司的股票，价值 65,998,000 美元，此前在上个季度又收购了 1,137,748 股。Driehaus Capital Management LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 192.0%。Driehaus Capital Management LLC 现在拥有 481,598 股该公司的股票，价值 18,238,000 美元，此前在上个季度又收购了 316,686 股。Vivo Capital LLC 在第二季度购买了价值约 7,048,000 美元的 Praxis Precision Medicines 新头寸。Woodline Partners LP 在第一季度将其在 Praxis Precision Medicines 的持股增加了 1,666.5%。Woodline Partners LP 现在拥有 175,727 股该公司的股票，价值 6,655,000 美元，此前在上个季度又购买了 165,779 股。最后，Aberdeen Group plc 在第二季度将其在 Praxis Precision Medicines 的持仓提高了 143.5%。Aberdeen Group plc 现在拥有 214,056 股该公司的股票，价值 9,001,000 美元，此前购买了 126,153 股。67.84% 的股票目前由机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other news, insider Lauren Mastrocola sold 13,600 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $192.08, for a total value of $2,612,288.00. Following the transaction, the insider directly owned 10,442 shares in the company, valued at approximately $2,005,699.36. This trade represents a 56.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Alex Nemiroff sold 25,130 shares of the business's stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $193.09, for a total value of $4,852,351.70. Following the completion of the transaction, the general counsel directly owned 20,832 shares of the company's stock, valued at approximately $4,022,450.88. The trade was a 54.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Lauren Mastrocola 于 11 月 20 日星期四出售了 13,600 股 Praxis Precision Medicines 的股票。该股票以平均价格 192.08 美元出售，总价值为 2,612,288.00 美元。交易完成后，内部人士直接持有该公司 10,442 股股票，价值约 2,005,699.36 美元。这笔交易代表其持仓减少了 56.57%。该出售在向 SEC 的法律文件中披露，可以通过此超链接访问。此外，法律顾问 Alex Nemiroff 于 11 月 20 日星期四出售了 25,130 股该公司的股票。该股票以平均价格 193.09 美元出售，总价值为 4,852,351.70 美元。交易完成后，法律顾问直接持有该公司 20,832 股股票，价值约 4,022,450.88 美元。这笔交易使其持有的股票减少了 54.68%。该出售的披露在 SEC 文件中可用。内部人士持有该公司 2.70% 的股票。</p>
</div><h2>Praxis Precision Medicines Price Performance</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 价格表现</h2>
</div><p>Shares of Praxis Precision Medicines stock opened at $261.58 on Thursday. The stock has a market cap of $6.54 billion, a price-to-earnings ratio of -20.28 and a beta of 2.95. The firm's 50-day moving average is $163.26 and its two-hundred day moving average is $87.46. Praxis Precision Medicines, Inc. has a 1 year low of $26.70 and a 1 year high of $278.44.</p>
<div class="lb-trans"><p>Praxis Precision Medicines 的股票在星期四开盘价为 261.58 美元。该股票的市值为 65.4 亿美元，市盈率为 -20.28，贝塔值为 2.95。该公司的 50 日移动平均线为 163.26 美元，200 日移动平均线为 87.46 美元。Praxis Precision Medicines, Inc. 的 1 年最低价为 26.70 美元，1 年最高价为 278.44 美元。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share for the quarter, topping the consensus estimate of ($3.45) by $0.09. On average, equities analysts expect that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（NASDAQ:PRAX - 获取免费报告）最近于 11 月 5 日星期三公布了季度财报。该公司报告每股收益为 -3.36 美元，超出市场共识预期的 -3.45 美元，超出幅度为 0.09 美元。分析师平均预计，Praxis Precision Medicines, Inc. 今年的每股收益将为 -10.22 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>PRAX has been the topic of a number of analyst reports. Lifesci Capital raised Praxis Precision Medicines to a &#34;strong-buy&#34; rating in a research note on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft restated a &#34;buy&#34; rating and set a $303.00 price objective on shares of Praxis Precision Medicines in a report on Friday, December 5th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Praxis Precision Medicines in a research note on Monday. TD Cowen boosted their target price on shares of Praxis Precision Medicines from $251.00 to $353.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Finally, Wedbush restated an &#34;underperform&#34; rating and issued a $83.00 price target (up from $77.00) on shares of Praxis Precision Medicines in a report on Friday, December 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, Praxis Precision Medicines has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $333.00.</p>
<div class="lb-trans"><p>PRAX 一直是多份分析师报告的主题。Lifesci Capital 在 9 月 3 日星期三的研究报告中将 Praxis Precision Medicines 的评级上调至 “强烈买入”。德意志银行在 12 月 5 日星期五的报告中重申了 “买入” 评级，并设定了 303.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对 Praxis Precision Medicines 的 “卖出（e+）” 评级。TD Cowen 在周一的研究报告中将 Praxis Precision Medicines 的目标价从 251.00 美元上调至 353.00 美元，并给予该公司 “买入” 评级。最后，Wedbush 在 12 月 5 日星期五的报告中重申了 “表现不佳” 评级，并将目标价设定为 83.00 美元（上调自 77.00 美元）。两位股票研究分析师对该股票给予了 “强烈买入” 评级，十三位给予了 “买入” 评级，两位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 333.00 美元。</p>
</div><p><strong>Get Our Latest Research Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Praxis Precision Medicines 的最新研究报告</strong></p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc. 是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行 III 期临床试验，治疗原发性震颤；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Praxis Precision Medicines</li>
<li>除息日对投资者的重要性是什么？</li>
<li>GameStop 看起来崩溃了：以下是 GME 可能在 2026 年崩盘的原因</li>
<li>CD 计算器：定期存款计算器</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Casey’s General Stores 将继续上涨的 3 个原因</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HighVista Strategies LLC 购买了 28,002 股 Praxis Precision Medicines, Inc. $PRAX 的股票